Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease
- 16 March 2004
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 19 (8), 937-942
- https://doi.org/10.1002/mds.20054
Abstract
We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo‐MTD). Twenty‐one PD patients were treated with levodopa plus oral dopamine‐agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo‐MTD (T2). Apo‐MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo‐MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add‐on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study. © 2004 Movement Disorder SocietyKeywords
This publication has 21 references indexed in Scilit:
- A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State EventsArchives of Neurology, 2001
- An algorithm (decision tree) for the management of Parkinson’s disease (2001):Neurology, 2001
- Apomorphine: An underutilized therapy for Parkinson's diseaseMovement Disorders, 2000
- A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's diseaseMovement Disorders, 1999
- Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Sublingual Apomorphine in Parkinsonʼs DiseaseClinical Neuropharmacology, 1991
- Absorption of apomorphine by various routes in parkinsonismMovement Disorders, 1991
- Intranasal apomorphine: a new treatment in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990